HEALEY ALS Platform Trial

Weekly Q&A – Feb 23, 2023

















Healey Center

Sean M. Healey & AMG Center for ALS at Mass General











































HEALEY ALS Platform Trial Goals:

- Screen new drugs rapidly and efficiently
- Get solid answers
- Determine next steps

Common Protocol
and Shared
Infrastructure

Regimen A

Regimen B

Regimen C

Regimen D

Regimen E

Regimen F

Regimen G



ENROLLMENT COMPLETE




IN START-UP



IN START-UP

Schema for Each Regimen



The HEALEY ALS Platform Trial is a unique opportunity to advance science



DNA – whole genome sequencing



Neurofilaments -for all regimens



Biomarkers (Blood, Urine, CSF) – several drug-specific biomarkers



Speech Analysis – emerging digital biomarker



Home Spirometry – critical during the pandemic

Additional biomarkers/outcome measures are being considered for upcoming regimens (e.g., new patient-reported outcomes; PBMCs for stem cell generation)

Recent RGD Press Release

PRESS RELEASE · FEB | 23 | 2023

Healey & AMG Center & the Northeast ALS Consortium announce results in platform trial with pridopidine

•••••

We are thankful to the many people who participated in this study and the staff at all the trial sites.

The positive results on speech and bulbar function, and on overall function and breathing in people earlier in disease course, are very encouraging and deserve further investigation in a phase III trial. This was a successful phase II trial where we learned a tremendous amount that will inform the follow-on clinical trials of pridopidine in ALS.

Merit Cudkowicz, MD, MSc

Director, Sean M. Healey & AMG Center for ALS, Massachusetts General Hospital

View Press Release:



https://bit.ly/3xSzBdG

Upcoming Webinars about Regimen D



Webinar for Participants in Regimen D

Monday, February 27th

Platform Trial sites will communicate details to their participants.



Community Webinar (Open to Public)

Monday, March 6th at 10:00 am Eastern Time


Register here: https://bit.ly/3KQ3q6L



Patient Navigation Central resource for people living with ALS



Catherine Small



Allison Bulat

Phone: 833-425-8257 (HALT ALS)

E-mail:healeyalsplatform@mgh.harvard.edu

Weekly webinar registration:



https://bit.ly/3r6Nd2L

ALS Link sign-up:



https://bit.ly/3o2Ds3m

Upcoming Webinars:

March 2nd- Weekly Q&A March 9th- Weekly Q&A